4-[(E)-2-(5,5,8,8-tetramethyl-3-thiophen-2-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid | 410528-40-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[(E)-2-(5,5,8,8-tetramethyl-3-thiophen-2-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid
• 英文别名: 4-[(E)-2-(5,5,8,8-tetramethyl-3-thiophen-2ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid；4-[(E)-2-[5,5,8,8-tetramethyl-3-(thiophen-2-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic acid
• CAS: 410528-40-4
• 化学式: C₂₈H₃₀O₂S
• 分子量: 430.611
• InChiKey: VFVVRLKFQBNMRM-FMIVXFBMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-formyl-3-[(thiophene-2-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene 、 ethyl (E)-4-{2-[3-((thiophene-2-yl)methyl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl]vinyl}benzoate 以63%的产率得到4-[(E)-2-(5,5,8,8-tetramethyl-3-thiophen-2-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid
  参考文献：
  名称：

  Retinoid compounds (I)

  摘要：

  当前的发明提供了新颖的视黄醇类化合物及其合成方法，治疗或预防肺气肿、癌症和皮肤病的方法，以及适用于治疗或预防肺气肿、癌症和皮肤病的药物组合物。

  公开号：

  US20020082265A1

文献信息

• Retinoids for the treatment of emphysema
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1935869A1

  公开（公告）日：2008-06-25

  The current invention provides novel retinoid compounds and methods for their synthesis, the use of such compounds for the preparation of medicaments for treating or preventing emphysema, cancer and dermatological disorders, methods for such deseases and pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders.

  本发明提供了新型维甲酸化合物及其合成方法，利用此类化合物制备治疗或预防肺气肿、癌症和皮肤病的药物，以及治疗此类疾病的方法和适用于治疗或预防肺气肿、癌症和皮肤病的药物组合物。
• Methods for treating multiple osteochondroma (MO)
  申请人：Clementia Pharmaceuticals Inc.

  公开号：US10980778B2

  公开（公告）日：2021-04-20

  The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.

  本发明的特点是通过向多发性骨软骨瘤（MO）患者施用帕罗伐汀（又称 R667）或其药学上可接受的盐，抑制骨软骨瘤的形成、减小其大小并减缓其生长。本文所述的方法还可以改善与MO患者骨软骨瘤形成和生长相关的并发症。
• RETINOIDS FOR THE TREATMENT OF EMPHYSEMA
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1324970A2

  公开（公告）日：2003-07-09
• METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO)
  申请人：Clementia Pharmaceuticals Inc.

  公开号：US20190275005A1

  公开（公告）日：2019-09-12

  The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.
• US6777418B2
  申请人：——

  公开号：US6777418B2

  公开（公告）日：2004-08-17